108
Participants
Start Date
December 31, 2011
Primary Completion Date
February 28, 2022
Study Completion Date
February 28, 2023
GM-CSF
GM-CSF is to be administered IV at one of four possible dosing regimens (three days at a dose of 30, 62, or 125 mcg/m2 per day, or an extended dosing regimen of 125 mcg/m2/day through post-trauma 6) if severe innate immune suppression is identified on post-trauma days 1, 2, or 3.
Children's Hospital of Pittsburgh, Pittsburgh
Children's Hospital of Philadelphia, Philadelphia
Children's National Medical Center, Washington D.C.
Nationwide Children's Hospital, Columbus
Cincinnati Children's Medical Center, Cincinnati
Children's Hospital of Michigan, Detroit
Washington University / St. Louis Children's Hospital, St Louis
Children's Hospital of Colorado, Aurora
National Institute of General Medical Sciences (NIGMS)
NIH
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Mark Hall
OTHER